Document Detail

Infliximab (remicade) and increased incidence of development of Basal cell carcinoma.
MedLine Citation:
PMID:  22527438     Owner:  NLM     Status:  In-Data-Review    
Immunosuppression is a known risk factor for the development of non-melanoma skin cancers (NMSC). Certain medications that induce immunosuppression, such as tumor necrosis factor-? (TNF-?) inhibitors, are being used more frequently. We report a case of a young, pregnant woman who was treated with infliximab for Crohn's disease, and subsequently experienced a rapid growth of two pre-existing basal cell carcinomas. As use of TNF-? inhibitors increases, it is important to closely monitor patients for the development of NMSC. J Drugs Dermatol. 2012;11(5):655-656.
Elizabeth Gaines-Cardone; Elizabeth K Hale
Related Documents :
22525818 - Angiotensin ii type i receptor and mir-155 in endometrial cancers: synergistic antiprol...
22693088 - [epidemiological, clinical and therapeutic features of hepatocellular carcinoma in cirr...
22550058 - Plasmacytoid urothelial carcinoma-diagnostic challenge in cytology.
24486738 - Iron homeostasis in breast cancer.
7333778 - The prevention and management of lymphoedema after treatment for breast cancer.
7262368 - The determinants of breast-feeding in sri lanka.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of drugs in dermatology : JDD     Volume:  11     ISSN:  1545-9616     ISO Abbreviation:  J Drugs Dermatol     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-04-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160020     Medline TA:  J Drugs Dermatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  655-6     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A new simple, safe, and easy solution for upper lip dermabrasion.
Next Document:  Treatment of mild to moderate facial melasma with the lumixyl topical brightening system.